Genesis Drug Discovery & Development (GD3) has expanded its drug development services through the acquisition of a majority interest in NexusPharma. The acquisition creates a fully-integrated portfolio of services for GD3 by integrating NexusPharma’s collection of patient-derived xenograft (PDX) models, with GD3’s existing platforms which include syngeneic/cell line derived xenograft models, radiotherapy, flow cytometry, and in-vivo imaging modalities. 
 
With direct access to primary patient-derived tumors, drug developers will have a clinically predictive method for validating cancer drug candidates. The application of NexusPharma’s primary patient-derived low passage tumors in concert with specialized PDX models, enhances drug development efforts. 
 
“The acquisition of NexusPharma is an important step in creating a novel suite of services for personalized medicine, including models for acquired resistance to targeted therapies,” said Dr. Eli Mordechai, CEO of GBG. In addition, NexusPharma’s ongoing partnership with FCCC will allow us to develop a comprehensive portfolio of services by building PDX models for unmet needs.